Stockscreener 앱 받기
6.995
64.49%
-12.70
시간 외 거래:
6.90
-0.095
-1.36%
Capricor Therapeutics Inc 주식(CAPR)의 최신 뉴스
CAPR Investor Alert: Kehoe Law Firm, P.C. Investigates Capricor T - The National Law Review
UPDATE: FDA disputes Capricor’s claims of Phase 3 success for DMD cell therapy - BioSpace
FDA staff report throws cold water on Capricor's DMD cell therapy bid - FirstWord Pharma
Capricor Therapeutics (NASDAQ:CAPR) Stock Rating Lowered by Roth Capital - MarketBeat
CAPR Stock On Track For Worst Day Ever — Analysts Divided On Deramiocel’s Approval Probability After FDA Documents Paint ‘Ugly Picture’ - Stocktwits
Capricor Therapeutics stock falls after FDA briefing ahead of AdCom By Investing.com - Investing.com Australia
Capricor Therapeutics stock falls after FDA briefing ahead of AdCom - Investing.com
Investigation launched into Capricor Therapeuti... - Pluang
Market movers: Nvidia, Advanced Micro Devices, Capricor Therapeutics, SpaceX… - Proactive financial news
Capricor stock plunges 70% after FDA questions trial data for heart therapy. - Pluang
Capricor Therapeutics Investors Who Suffered Losses Are Encouraged to Contact Johnson Fistel - GlobeNewswire
Capricor Therapeutics Investors Who Suffered Losses Are Encouraged to Contact Johnson Fistel - GlobeNewswire Inc.
CAPR INVESTOR ALERT: Investigation of Capricor Therapeutics, Inc. Announced by Holzer & Holzer, LLC - GlobeNewswire
H.C. Wainwright reiterates Capricor stock Buy rating at $60 target - Investing.com
Capricor Therapeutics Shares Dive Before Key Review as FDA Panel Challenges Data - Benzinga
FDA briefing casts doubt on Capricor's deramiocel ahead of D - AllSci
Capricor Therapeutics faces securities fraud pr... - Pluang
B.Riley downgrades Capricor stock on FDA briefing concerns - Investing.com
BREAKING: Capricor Therapeutics Investigated for Securities - GlobeNewswire
Capricor Therapeutics’ 67.7% collapse and the warning signs that preceded it - Investing.com
$Capricor Therapeutics (CAPR.US)$ waaa hit my first 🎯 - Moomoo
Capricor Therapeutics (NASDAQ:CAPR) Receives Neutral Rating from B. Riley Financial - MarketBeat
Capricor Therapeutics (CAPR) Shares Plunge 67% After FDA Briefin - GuruFocus
B.Riley downgrades Capricor stock on FDA briefing concerns By Investing.com - Investing.com Canada
FDA scientists question Capricor data; Legend CEO steps down - BioPharma Dive
Capricor Therapeutics (CAPR) Downgraded as FDA Briefing Raises Approval Concerns - GuruFocus
Capricor Therapeutics (NASDAQ:CAPR) shares tumble 67% after FDA raises concerns over Deramiocel data - TechStock²
Capricor Says FDA Used 'Obsolete' Analysis In Deramiocel Review – CAPR Stock Plummets After Agency Released Briefing Document - Stocktwits
Oppenheimer reiterates Capricor stock rating ahead of FDA panel By Investing.com - Investing.com South Africa
Capricor addresses FDA briefing materials ahead of advisory meeting By Investing.com - Investing.com South Africa
FDA staff flags data concerns about Capricor's therapy; shares plunge - Reuters
Capricor Therapeutics stock tumbles after FDA briefing documents - Investing.com
Capricor updates ahead of FDA advisory meeting on Duchenne muscular dystrophy therapy Deramiocel. - Pluang
Capricor Provides Update on Deramiocel for DMD Ahead of FDA Meeting - Intellectia AI
Capricor Therapeutics Provides Update Ahead of FDA Advisory Committee Meeting on Deramiocel BLA for Duchenne Muscular Dystrophy - Quiver Quantitative
Capricor Therapeutics (CAPR) Shares Plunge Amid FDA Data Concerns, GF Score™ at 28 - GuruFocus
Capricor shares drop 67% after FDA questions Du... - Pluang
Capricor Comments on Briefing Materials Ahead of July 29 FDA Advisory Committee Meeting for Deramiocel - Yahoo Finance
Capricor plunges on FDA AdCom briefing doc for Duchenne treatment - Seeking Alpha
Capricor Therapeutics shares plunge after FDA releases briefing documents - Yahoo Finance
FDA staff flags concerns about Capricor’s Duchenne heart disease therapy - 1470 & 100.3 WMBD
Capricor Therapeutics Stock Plunges After FDA Releases Briefing Documents - Benzinga
Ahead of hearing, FDA questions the efficacy of Capricor’s Duchenne drug - STAT
FDA staff flags concerns for Capricor’s Duchenne heart disease therapy - whbl.com
Capricor Therapeutics Inc (CAPR) Cash Flow - TradingKey
Capricor Therapeutics stock tumbles after FDA briefing documents By Investing.com - Investing.com South Africa
How FDA‑Linked HQ and Manufacturing Expansion At Capricor Therapeutics (CAPR) Has Changed Its Investment Story - Yahoo Finance
SpaceX Stock Price Today | SPCX Ticker, News, Retail Sentiment - Stocktwits
Capricor Therapeutics shares tumble after FDA reviewers raise concerns over Duchenne therapy - Proactive financial news
Is Capricor Therapeutics (CAPR) Trading At A Discount After Its Lease Deal And FDA Wait? - Yahoo Finance
Capricor Therapeutics Inc (CAPR) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
FDA has recommitted to adcomms—but to what end? - BioSpace
Capricor Therapeutics Inc (CAPR) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Capricor Therapeutics (CAPR) Secures New Headquarters Tied To FDA Decision On Deramiocel - simplywall.st
Capricor Therapeutics (CAPR) Stock Looks Fully Priced For Now - Yahoo Finance
What is the latest on Capricor Therapeutics' Deramiocel and its FDA journey - Kavout | AI
Securities Lawsuit Alert: Capricor Therapeutics, Inc. (CAPR) Inve - The National Law Review
S&P 500, Dow, Nasdaq Futures Climb As Trump Says Iran Ceasefire Holds Despite Fresh Hormuz Tensions: IREN, CRWV, CAPR, TTD Stocks In Focus - Stocktwits
Capricor Or Sarepta: Two DMD Stocks Enter A High-Stakes Week – Which One Has More Upside? - Stocktwits
This Capricor Insider Sold 24,000 Shares Before the Drop. With a New Catalyst on the Way, Is It Time to Buy? - The Motley Fool
CAPR Stock Draws Investor Attention After AAN Presentation For DMD Therapy - Stocktwits
CAPR|Capricor Therapeutics Inc|Price:19.700|Chg%:-0.130 - TradingKey
CAPR Stock Gains Steam: Former Capricor Exec Could Become FDA’s Top Gene Therapy Regulator Ahead Of High-Stakes DMD Decision - Stocktwits
Capricor Therapeutics, Inc. Revenue Breakdown – NASDAQ:CAPR - TradingView
FDA Showdown Week: CAPR, NRXP, REPL And MRNA Face Make-Or-Break Regulatory Decisions - Yahoo Finance
Stock Traders Purchase Large Volume of Call Options on Capricor Therapeutics (NASDAQ:CAPR) - MarketBeat
Behavioral Patterns of CAPR and Institutional Flows - Stock Traders Daily
Capricor Therapeutics, Inc. (CAPR) Stock Analysis: Exploring the 170% Upside Potential in Biotech Innovation - DirectorsTalk Interviews
Capricor Therapeutics, Inc. (NASDAQ:CAPR) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Capricor Therapeutics Inc (CAPR) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
1.97%
0.83%
자본화:
|
볼륨(24시간):